Jazz Pharmaceuticals plc has disclosed a substantial pre-tax charge of approximately $755 million related to its acquisition of Actio Biosciences, Inc. This financial impact is expected to significantly affect the company's earnings per share (EPS) for the third quarter of 2026.
The charge, primarily attributed to acquired in-process research and development (IPR&D) expenses, is estimated to decrease both GAAP and non-GAAP adjusted EPS by about $11.00. The company completed the acquisition of Actio on September 15, 2026.
Background
Jazz Pharmaceuticals plc, a prominent player in the pharmaceutical preparations industry (SIC 2834), is headquartered in Dublin, Ireland. The company is listed on the Nasdaq under the ticker symbol JAZZ. As a large accelerated filer, Jazz is subject to rigorous reporting requirements and has a fiscal year ending on December 31.
What the Filing Says
The recent SEC filing states, "Jazz Pharmaceuticals currently estimates that its GAAP and non-GAAP financial results for the third quarter of 2026 will include a pre-tax charge of approximately $755 million of acquired in-process research and development (IPR&D) expense." This charge is not tax-deductible and is expected to have a significant negative impact on the company's financial performance for the quarter.
Impact
The estimated charge may affect investors' perceptions of Jazz Pharmaceuticals, particularly regarding its financial health and future growth potential. The pharmaceutical industry, which is often scrutinized for its acquisition strategies, may also face increased attention as companies navigate the implications of similar financial burdens.
What's Next
The filing does not say what happens next. However, the company’s results for the quarter ended September 30, 2026, are not yet finalized and remain subject to its financial statement closing procedures.